JWJiangrong Wang

Jiangrong Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jiangrong Wang has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Letter Re: Diagnostic testing accuracy of DNA methylation tests for detection of high-grade cervical intraepithelial neoplasia and cervical cancer: A systematic review and meta-analysis

    by Martin Widschwendter, Joakim Dillner, Karin Sundström, Jiangrong Wang, James E. Barrett, Elisa Redl, Chiara Herzog, Charlotte Vavourakis, Lena Schreiberhuber


  • Open Access

    Invasive Cervical Cancers After an HPV ‐Negative Test: Insights From HPV Testing Histories

    by Sadaf Sakina Hassan, Sara Nordqvist Kleppe, Nijin Asinger, Jiangrong Wang, Joakim Dillner, Laila Sara Arroyo Mühr

    Human papillomavirus (HPV) testing is the primary method for cervical screening, and a negative HPV test is associated with a very low subsequent risk of invasive cancer. Nevertheless, some cervical cancers are diagnosed following an HPV‐negative test. Using Swedish registry data, we identified women diagnosed with invasive cervical cancer between 2019 and 2024 and reconstructed HPV testing histories from the National Cervical Screening Registry. The HPV test closest to diagnosis, performed before or within 30 days after diagnosis, was defined as the index test. Of 3000 women diagnosed with invasive cervical cancer, 243 (8.1%) had an HPV‐negative index test. These women were older and more frequently diagnosed at advanced stages than women with an HPV‐positive index test. After adjustment for age, calendar year, and histology, an HPV‐negative index test remained associated with advanced‐stage disease (adjusted OR 2.91, 95% CI: 2.13–4.00). Among women with an HPV‐negative index test, 128 of 243 (52.7%) had no prior HPV testing recorded, 83 of 243 (34.2%) had consistently HPV‐negative histories, and 32 of 243 (13.2%) had prior HPV positivity. Cytology records were available for 229 to 243 (94.2%), and 33 to 243 (13.6%) had a previous high‐grade histopathological diagnosis. Among women with an HPV‐negative index test, recurrent HPV positivity following an intervening negative test was observed in only one woman. Cervical cancers diagnosed after an HPV‐negative test reflect heterogeneous HPV testing histories. Most women either had no prior HPV testing recorded or had consistently HPV‐negative results, while HPV positivity was observed in a smaller subgroup.

  • Open Access

    Risk of Invasive Cervical Cancer After Prevalent, Incident or Persistent Detection of Human Papillomavirus

    by Jiangrong Wang, K. Miriam Elfström, Joakim Dillner

    Background: Persistent infection of oncogenic Human Papillomavirus (HPV) types is the primary cause of cervical cancer. HPV-based cervical screening is globally recommended. Management of positive screening results depends on cervical cancer risk. Current risk stratification is mostly based on evidence from the first round of HPV screening (prevalent screen), whereas incident HPV detections in subsequent screening rounds by HPV type may differ substantially. Empirical evidence is limited.Methods: We examined the cumulative incidence proportion (CIP) of invasive cervical cancer (ICC) and high-grade precancers following prevalent, incident and persistent HPV detection by HPV genotype, in all women aged 23-70 resident in Stockholm, Sweden, from 2014-2024 (N=1,060,789). Individual-level screening and cancer data were linked between healthcare registers.Findings: There were 86,445 prevalent (without prior HPV test), 18,166 incident (with a prior negative HPV), and 15,237 persistent (with a prior positive HPV) detections. CIPs of ICC by 6 years after prevalent and incident HPV detections were 0·70% and 0·15%, adjusted hazard ratios (aHR) 9·79 (95%CI:5·36-17·89). Corresponding CIPs for precancers were 20·75% and 8·41%, aHR 3·50 (95%CI:3·23-3·79). Assuming no immediate management, the estimated CIPs of ICC in 3-4 years after persistent HPV16/18 detection were approximately 23%, whereas those following incident HPV35/39/51/56/66/68 were less than 0·3%.Interpretation: Optimal management strategies in HPV-based cervical screening may be different between the first round of HPV screening and the subsequent screens. Combining data on prior HPV testing and HPV genotype yields distinct risk estimates for management strategy.

  • Open Access

    Incidence of Recurrent Respiratory Papillomatosis (RRP) in Denmark and Sweden During 2000-2023: Two Nationwide Cohort Studies in Children and Young Adults

    by Karin Sundström, Christian Munk, Jiangrong Wang, Kirsten Frederiksen, Sara Nordqvist Kleppe, Parag Mahale, Joseph E Tota, Susanne K Kjær

    Introduction: Recurrent respiratory papillomatosis (RRP), primarily caused by human papillomavirus (HPV) types 6 or 11, is a rare but high-morbidity condition. Nationwide estimates of the incidence of RRP are scarce, and we aimed to estimate the incidence of RRP among children and young adults in Denmark (2000-2023) and Sweden (2000-2021). Methods: Using the Danish Pathology Register and the Swedish Patient Register, we identified all individuals with a first-time occurrence of RRP (definition in Denmark: histologically confirmed, topography code T24 plus SNOMED codes for papillomas; Sweden: International Classification of Diseases-10 code D14.1A for papillomas). Incidence rates were calculated as number of RRP cases per 100 000 person-years (py), stratified by country, sex, and age groups at onset (0-14/juvenile 15-29/adult). Trends in incidence were evaluated in the period before and after introduction of HPV vaccination using Poisson regression to estimate the annual percentage change (APC) and 95% confidence intervals (CI). Results: We found juvenile-onset RRP incidences of 0.14 to 0.20/100 000 py as well as adult-onset RRP incidences at 0.19 to 0.40/100 000 py for women and 0.52 to 0.68/100 000 py for men in the postvaccine introduction period. Danish data showed a decreasing trend in RRP during the period following implementation of HPV vaccination, especially among young adults (women: APC = −11.5 [95% CI, −20.9 to −0.9]; men: APC = −11.0 [95% CI, −16.6 to −4.9]), whereas Swedish data did not show any clear decrease in RRP over time. Conclusions: The incidence of RRP is decreasing in Denmark but not in Sweden. This may be the result of more intense HPV vaccination programs, in particular early catchup vaccination of young adults, in Denmark as compared to Sweden.

  • Open Access

    Invasive cervical cancers after an HPV-negative test: insights from screening histories

    by Sadaf Sakina Hassan, Sara Nordqvist-Kleppe, Nijin Asinger, Jiangrong Wang, Joakim Dillner, Laila Sara Arroyo Muhr

    Human papillomavirus (HPV) testing is the primary method for cervical cancer screening, and a negative HPV test is associated with a very low subsequent risk of invasive cancer. Nevertheless, a small number of cervical cancers are diagnosed following an HPV-negative testing result, posing challenges within HPV-based screening pathways. Using nationwide Swedish registry data of HPV testing, we identified women diagnosed with invasive cervical cancer between 2019 and 2024 and reconstructed HPV testing histories from the National Cervical Screening Registry (NKCx). The most recent HPV test prior to diagnosis was defined as the index test, and longitudinal HPV testing trajectories were classified among women with an HPV-negative index test. Of 3,000 women diagnosed with invasive cancer, 243 (8.1%) had an HPV-negative index test. These women were older at diagnosis and more frequently diagnosed at advanced stages compared with women with an HPV-positive index test. Most HPV-negative index tests (66.3%) were performed in the peri-diagnostic period (+/- 30 days). Among women with an HPV-negative index test, 52.7% (128/243) had no prior HPV testing recorded, while the remainder had consistently HPV-negative histories (33.3%, 83/243) or evidence of prior HPV positivity before the index negative test (14%, 32/243). Possible recurrent HPV positivity following an intervening negative test was rare (0.4%, 1/243). HPV-negative screening results preceding invasive cancer reflect heterogeneous screening histories and cannot be explained solely by test failure. Findings highlighting the importance of reaching women earlier in screening programs and show that fluctuating HPV detectability is rare.


  • Open Access

    Nationwide audit of cervical cancer screening reveals unsatisfactory triage strategies and trends over time in incidence among cytology negative women

    by Cecilia Kärrberg, Penelope Gray, Kristina Elfgren, Hanna Milerad, Bengt Andrae, Jiayao Lei, Pär Sparén, Joakim Dillner, Jiangrong Wang, K. Miriam Elfström

    Regular audits are essential for monitoring and evaluation of cervical screening. We audited the Swedish cervical screening program during the transition to HPV‐based screening using a registry‐based cohort design. In total, 5689 consecutive, confirmed cases of invasive cervical cancer between 2012 and 2022 were retrieved from the Swedish Quality Register for Gynecological Cancer. Their screening history, screening status, invitations to cervical screening, all diagnoses in screening cytology and HPV genotypes were retrieved from the Swedish National Cervical Screening Registry. Furthermore, all cancer cases during 2018–2022 were classified according to their screening history and the age‐standardized cervical cancer incidence rate stratified by screening history and calendar year was calculated among the cohort of all women in Sweden ages 29–84. Non‐participation remains the main process related history with high risk of cancer (cervical cancer incidence rate, IR, among non‐attenders was 33.9 [95% confidence intervals, 95% CI, 28.2–39.5] per 100,000 person‐years, /100,000PY, representing 31% of cases in 2022). The cervical cancer IR after negative cytology increased with calendar time (IR = 5.5 [95% CI, 4.1–6.8]/100,000PY in 2012 and 11.5 [8.1–14.9]/100,000PY in 2022) and was high after a positive HPV test followed by negative cytology triage (IR = 56.7 [39.9–73.6] in 2022). In conclusion, this comprehensive audit has identified a decreasing protection by the screening test under discontinuation (cytology) and that the performance as a triage test after HPV‐testing is unsatisfactory.


  • Open Access

    Mental disorders and socioeconomic outcomes in women with cervical cancer, and their children and co-parents

    by Jiangrong Wang, Stina Salomonsson, Demet Sönmez, Sara Nordqvist Kleppe, Adina L Feldman, Marcus Sven Andersson, Goran Bencina, Fang Fang, Karin Sundström

    Background: Cervical cancer often affects women who are in the middle of life and may carry substantial mental and socioeconomic impact also on families. We performed a generation-spanning study to elucidate this burden. Methods: We used nationwide registers during 1991-2018 in Sweden to perform 2 matched cohort studies based on a source population of more than 5 million women. The individual sub-study included 6060 cases of cervical cancer diagnosed during 2006-2018 and 5 population comparators individually matched to each case by age, birth year, and region (n = 30 300). The family sub-study included 9332 cases of cervical cancer diagnosed during 1991-2016 and 45 674 matched population comparators and all their children and co-parents. Results: We found an increased risk for mental disorders in cases compared with comparators, particularly during the first 2 years postdiagnosis (HR = 3.74, 95% CI = 3.45 to 4.06). Socioeconomic status changed negatively in cases after their diagnosis: a decreased income and increased need for financial aid appeared within 2 years, whereas unemployment escalated from 2 years after cancer diagnosis. We further found an increased risk of mental disorders in both children and co-parents of the cases, compared with the children and co-parents of the comparators. Furthermore, we observed negative socioeconomic trajectories in the co-parents and lower educational attainment in the children of the cases, especially if the case had died. Conclusions: Women with cervical cancer, and their close family members, display increased risk of negative mental health and socioeconomic outcomes after diagnosis. The lower educational attainment in children appears particularly worrying.


  • Open Access

    Population-Based Age-Period-Cohort Analysis of Declining Human Papillomavirus Prevalence

    by Penelope Gray, Jiangrong Wang, Sara Nordqvist Kleppe, K Miriam Elfström, Joakim Dillner

    Background: Most countries in the world have launched human papillomavirus (HPV) vaccination programs, and declining HPV prevalences are reported. We aimed to disentangle the influences of calendar time, birth cohort, and age by analyzing HPV prevalences in the population-based cervical screening program using age-period-cohort modeling. Methods: All 813 882 primary HPV-based cervical screening tests from women aged 23–64 years between 2014 and 2023 in the capital region of Sweden were identified in the Swedish National Cervical Screening Registry. The odds ratio (OR) of HPV-16/18 infection was estimated comparing birth cohorts to the unvaccinated 1984-born using an age-period-cohort model. The impact of changing HPV prevalences on the number needed to screen (NNS) to detect and prevent 1 cervical cancer case was calculated. Results: HPV vaccination coverage was 82%–83% among women born in 1999–2000. Before 2019, the HPV-16/18 prevalence was highest among the youngest women. During 2020–2023 the prevalence consistently decreased among the birth cohorts offered organized school-based vaccination. There was a 98% decline in HPV-16 prevalence (OR, 0.02 [95% confidence interval {CI}, .01–.04]) and a 99% decline in HPV-18 prevalence (OR, 0.01 [95% CI, .00–.04]) among the 2000-born compared to the 1984-born. The declining HPV-16/18 prevalences resulted in major increases in the NNS to detect and to prevent 1 case of cervical cancer. Conclusions: The declines of HPV-16/18 were considerably larger than the vaccination coverage, suggesting herd immunity. The changing epidemiology of HPV types impacts screening needs, necessitating updated screening programs.


  • Open Access

    Evaluation of primary HPV-based cervical screening among older women: Long-term follow-up of a randomized healthcare policy trial in Sweden

    by Qingyun Yao, Jiangrong Wang, K Miriam Elfström, Björn Strander, Joakim Dillner, Karin Sundström

    Background: Evidence on invasive cervical cancer prevention among older women is limited, especially with the introduction of human papillomavirus (HPV)-based screening and longer interval. We conducted a long-term follow-up of the first phase of a randomized healthcare policy trial in cervical screening, targeting women aged 56 to 61 years old, to investigate the effectiveness of primary HPV-based screening in preventing invasive cervical cancer (ICC) and the safety of extending screening interval. Methods and findings: The randomized healthcare policy trial of primary HPV-based cervical screening targeted women residing in Stockholm-Gotland region during 2012 to 2016, aged 30 to 64 years. The trial aimed to investigate the detection rate of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) within 24 months and long-term protection against invasive cervical cancer, comparing primary HPV-based screening to primary cytology-based screening. The initial phase of the trial, which was the focus of this study, targeted women aged 56 to 61 years old in 2012 to 2014 who were randomized to primary cytology arm (n = 7,401) or primary HPV arm (n = 7,318). We used national registries to identify the subsequent cervical tests and all histopathological diagnoses including ICC before December 31, 2022. We calculated cumulative incidence, incidence rate (IR) and IR ratio (IRR) of ICC, by baseline test result. Furthermore, we calculated longitudinal sensitivity and specificity for detecting cervical intraepithelial neoplasia grade 2 or worse (CIN2+) by receipt of primary cytology or primary HPV test for the recommended screening intervals in this age group. We found that the IR of ICC among women in the primary HPV arm was 7.2/100,000 person-years (py) and 3.0 for women who tested HPV negative, compared to 18.4/100,000 py among women in the primary cytology arm and 18.8 for women who tested cytology negative. We further found that the overall point estimate for the risk of ICC over 10 years of follow-up among women in the primary HPV arm was 0.39 compared to women in the primary cytology arm, but this was not statistically significant (IRR: 0.39; 95% confidence interval, CI [0.14, 1.09]; p = 0.0726). However, among women with a negative test result at baseline, women in the primary HPV arm had an 84% lower risk of ICC compared to women in the primary cytology arm (IRR: 0.16; 95% CI [0.04, 0.72]; p = 0.0163). Moreover, primary HPV testing had a higher sensitivity for detecting CIN2+ within a 7-year interval than primary cytology testing within a 5-year interval (89.6% versus 50.9%, p < 0.0001). We were limited by a partial imbalance of invitations during the follow-up between the 2 arms which may have led to an underestimation of the effectiveness of primary HPV-based screening. Conclusions: In this study, we observed that women over 55 years of age who received a primary negative HPV test result had substantially lower risk of CIN2+, and ICC, compared to women who received a primary negative cytology result. This should apply even if the screening interval were prolonged to 7 years. Trial Registration: NCT01511328.


  • Open Access

    Nationwide registry‐based trial of risk‐stratified cervical screening

    by Laila Sara Arroyo Mühr, Jiangrong Wang, Sadaf S. Hassan, Emel Yilmaz, Miriam K. Elfström, Joakim Dillner

    In well‐screened populations, most cervical cancers arise from small groups of women with inadequate screening. The present study aims to assess whether registry‐based cancer risk assessment could be used to increase screening intensity among high‐risk women. The National Cervical Screening Registry identified the 28,689 women residents in Sweden who had either no previous cervical screening or a screening history indicating high risk. We invited these women by SMS and/or physical letter to order a free human papillomavirus (HPV) self‐sampling kit. The Swedish national HPV reference laboratory performed extended HPV genotyping and referred high‐risk HPV‐positive women to their regional gynecologist. A total of 3691/28,689 (12.9%) women ordered a self‐sampling kit and 10.0% (2853/28,689) returned a sample for testing. Participation among women who had never attended screening was low, albeit improved. Up to 22.5% of women in other high‐risk groups attended. High‐risk HPV types were detected in 8.3% of samples. High‐risk HPV‐positive women (238/2853) were referred without further triaging and severe cervical precancer or cancer (HSIL+) in histopathology were detected in 36/158 (23%) of biopsied women. Repeat invitations gave modest additional participation. Nationwide contacting of women with high risk for cervical cancer with personal invitations to order HPV self‐sampling kits resulted in high yield of detected CIN2+. Further efforts to improve risk‐stratified screening strategies should be directed to improving (i) the precision of the risk‐stratification algorithm, (ii) the convenience for the women to participate and, (iii) ensuring that screen‐positive women are followed‐up.